Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

This article has been updated

Abstract

The prevalence of dementia in the Western world in people over the age of 60 has been estimated to be greater than 5%, about two-thirds of which are due to Alzheimer’s disease1,2,3,4. The age-specific prevalence of Alzheimer’s disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3). Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer’s disease, we studied coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders. We found a coding mutation (A673T) in the APP gene that protects against Alzheimer’s disease and cognitive decline in the elderly without Alzheimer’s disease. This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The strong protective effect of the A673T substitution against Alzheimer’s disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease. Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer’s disease, the two may be mediated through the same or similar mechanisms.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Cognition measured by CPS as a function of age.
Figure 2: A673T reduces BACE1 cleavage of APP.

Similar content being viewed by others

Change history

  • 01 August 2012

    A minor error relating to the rs63750847 variant in ref. 15 was corrected.

References

  1. Ferri, C. P. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112–2117 (2005)

    Article  Google Scholar 

  2. Plassman, B. L. et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29, 125–132 (2007)

    Article  CAS  Google Scholar 

  3. Qiu, C., Kivipelto, M. & von Strauss, E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin. Neurosci. 11, 111–128 (2009)

    PubMed  PubMed Central  Google Scholar 

  4. Reitz, C., Brayne, C. & Mayeux, R. Epidemiology of Alzheimer disease. Nature reviews . Neurology 7, 137–152 (2011)

    PubMed  Google Scholar 

  5. Glenner, G. G. & Wong, C. W. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885–890 (1984)

    Article  CAS  Google Scholar 

  6. Masters, C. L. et al. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer’s disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4, 2757–2763 (1985)

    Article  CAS  Google Scholar 

  7. Zhang, Y. W., Thompson, R., Zhang, H. & Xu, H. APP processing in Alzheimer’s disease. Mol. Brain 4, 3 (2011)

    Article  CAS  Google Scholar 

  8. Hussain, I. et al. Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol. Cell. Neurosci. 14, 419–427 (1999)

    Article  CAS  Google Scholar 

  9. Sinha, S. et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 402, 537–540 (1999)

    Article  ADS  CAS  Google Scholar 

  10. Vassar, R. et al. β-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741 (1999)

    Article  CAS  Google Scholar 

  11. Yan, R. et al. Membrane-anchored aspartyl protease with Alzheimer’s disease β-secretase activity. Nature 402, 533–537 (1999)

    Article  ADS  CAS  Google Scholar 

  12. Hardy, J. C. & Crook, R. APP mutations table. http://www.alzforum.org/res/com/mut/app/table1.asp (2010)

  13. Cruts, M. Alzheimer’s disease and frontotemporal dementia mutation database. http://www.molgen.ua.ac.be/ADMutations (2012)

  14. St George-Hyslop, P. H. Molecular genetics of Alzheimer’s disease. Biol. Psychiatry 47, 183–199 (2000)

    Article  CAS  Google Scholar 

  15. Cruchaga, C. et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s disease families. PLoS ONE 7, e31039 (2012)

    Article  ADS  CAS  Google Scholar 

  16. Kong, A. et al. Detection of sharing by descent, long-range phasing and haplotype imputation. Nature Genet. 40, 1068–1075 (2008)

    Article  CAS  Google Scholar 

  17. Kong, A. et al. Fine-scale recombination rate differences between sexes, populations and individuals. Nature 467, 1099–1103 (2010)

    Article  ADS  CAS  Google Scholar 

  18. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nature Genet. 39, 906–913 (2007)

    Article  CAS  Google Scholar 

  19. Sulem, P. et al. Identification of low-frequency variants associated with gout and serum uric acid levels. Nature Genet. 43, 1127–1130 (2011)

    Article  CAS  Google Scholar 

  20. Peacock, M. L., Warren, J. T., Jr, Roses, A. D. & Fink, J. K. Novel polymorphism in the A4 region of the amyloid precursor protein gene in a patient without Alzheimer’s disease. Neurology 43, 1254–1256 (1993)

    Article  CAS  Google Scholar 

  21. Exome Variant Server. NHLBI Exome Sequencing Project (ESP). http://evs.gs.washington.edu/EVS/ (2012)

  22. Di Fede, G. et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 323, 1473–1477 (2009)

    Article  ADS  CAS  Google Scholar 

  23. Giaccone, G. et al. Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Acta Neuropathol. 120, 803–812 (2010)

    Article  CAS  Google Scholar 

  24. Citron, M. et al. Mutation of the β-amyloid precursor protein in familial Alzheimer’s disease increases β-protein production. Nature 360, 672–674 (1992)

    Article  ADS  CAS  Google Scholar 

  25. Gruninger-Leitch, F., Schlatter, D., Kung, E., Nelbock, P. & Dobeli, H. Substrate and inhibitor profile of BACE (β-secretase) and comparison with other mammalian aspartic proteases. J. Biol. Chem. 277, 4687–4693 (2002)

    Article  CAS  Google Scholar 

  26. Tomasselli, A. G. et al. Employing a superior BACE1 cleavage sequence to probe cellular APP processing. J. Neurochem. 84, 1006–1017 (2003)

    Article  CAS  Google Scholar 

  27. Morris, J. N. et al. MDS Cognitive Performance Scale. J. Gerontol. 49, M174–M182 (1994)

    Article  CAS  Google Scholar 

  28. Holm, H. et al. A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nature Genet. 43, 316–320 (2011)

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank the NHLBI GO Exome Sequencing Project and its ongoing studies, which produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926) and the Heart GO Sequencing Project (HL-103010).

Author information

Authors and Affiliations

Authors

Contributions

The study was designed and results were interpreted by T.J., J.K.A., H.S., R.J.W. and K.S. Sequence data analysis was carried out by T.J., S.S., P.S., A.K., T.B., R.R.G., T.W.B. and D.G. Subject recruitment, phenotype analysis and biological material collection was organized and carried out by J.S., P.V.J., S.B., G.B., O.A.A., E.G.J. and A.P. Sequencing and genotyping was supervised by J.H., O.T.M. and U.T. Cell line experiments and BACE1 cleavage assays were carried out and analysed by J.K.A., J.M., K.H., Y. Lu, Y. Liu, A.G. and R.J.W. The paper was drafted by T.J., J.K.A., R.J.W. and K.S. All authors contributed to the final version of the paper.

Corresponding author

Correspondence to Kari Stefansson.

Ethics declarations

Competing interests

Authors from deCODE and Genentech are employees of deCODE genetics, ehf and Genentech, respectively.

Supplementary information

Supplementary Information

This file contains Supplementary Text and Data, Supplementary Tables 1-2, Supplementary Figures 1-4 and Supplementary References. (PDF 998 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jonsson, T., Atwal, J., Steinberg, S. et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488, 96–99 (2012). https://doi.org/10.1038/nature11283

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature11283

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing